| | |
| Clinical data | |
|---|---|
| Other names | PRX14040 |
| Drug class | Dopamine reuptake inhibitor; Pro-motivational agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H22Cl3NO2 |
| Molar mass | 378.72 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PRX-14040 is a selective dopamine reuptake inhibitor that was developed by Prexa Pharmaceuticals. [1] [2] [3] It has 28-fold selectivity for the dopamine transporter over the norepinephrine transporter. [2] Similarly to various other dopamine reuptake inhibitors, the drug has been found to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine in animals. [1] [2]